A5074276689- Prostate Cancer Treatment and Research
- Cancer-related molecular mechanisms research
- RNA modifications and cancer
- Cancer, Lipids, and Metabolism
- Estrogen and related hormone effects
- Cytokine Signaling Pathways and Interactions
- Ubiquitin and proteasome pathways
- Tannin, Tannase and Anticancer Activities
- RNA Interference and Gene Delivery
- Protein Degradation and Inhibitors
- Cancer Cells and Metastasis
- Steroid Chemistry and Biochemistry
- Epigenetics and DNA Methylation
- Ferroptosis and cancer prognosis
- RNA Research and Splicing
- Cholesterol and Lipid Metabolism
- Cancer-related gene regulation
- MicroRNA in disease regulation
- Cancer, Hypoxia, and Metabolism
- Molecular Biology Techniques and Applications
- DNA and Nucleic Acid Chemistry
- Genomics and Chromatin Dynamics
- Circular RNAs in diseases
- Renal and related cancers
- Extracellular vesicles in disease
Università della Svizzera italiana
2017-2024
Institute of Oncology Research
2015-2024
University of Naples Federico II
2024
University of Insubria
2012-2013
University of Bern
2012-2013
University Hospital of Bern
2012-2013
Fondazione Edo ed Elvo Tempia
2012-2013
University of Turin
2012
Mylan (Switzerland)
2012
MultiMedica
2012
Background ETS transcription factors regulate important signaling pathways involved in cell differentiation and development many tissues have emerged as players prostate cancer. However, the biological impact of tumorigenesis is still debated. Methodology/Principal Findings We performed an analysis gene family using microarray data real-time PCR normal tumor along with functional studies cancer lines to understand identify key targets these factors. found frequent dysregulation genes...
Cancer stem cells (CSC) play a significant role in tumor progression, disease recurrence, and treatment failure. Here, we show that the endogenously expressed ETS transcription factor ESE3/EHF controls prostate epithelial cell differentiation stem-like potential. We found loss of induced epithelial-to-mesenchymal transition (EMT), features, tumor-initiating metastatic properties cells, reexpression inhibited tumorigenic potential cancer cells. Mechanistically, repressed expression key EMT...
Significance The transcription factor STAT3 is involved in multiple oncogenic signaling pathways and an attractive therapeutic target. This study shows that a potent inhibitor of interferes with mitochondrial activity protein homeostasis, leading to synthetic lethality effect glucose-depleted cancer cells. These findings provide rationale for novel strategies based on the use inhibitors treatment.
Several studies link disease progression, recurrence, and treatment failures to the cancer stem-like cell (CSC) subpopulation within heterogeneous tumor population. Myc is a transcription factor having central function in stem biology human cancers. Hence, represents an attractive target develop CSC-specific therapies. Recent findings suggest that can be silenced using RNA interference (RNAi)-based strategy targets noncoding promoter-associated (paRNA) overlapping start site. In this study,...
STAT3 is a key element in many oncogenic pathways and, like other transcription factors, an attractive target for development of novel anticancer drugs. However, interfering with functions has been difficult task and very few small molecule inhibitors have made their way to the clinic. OPB‐31121, compound currently clinical trials, reported affect signaling, although its mechanism action not unequivocally demonstrated. In this study, we used combined computational experimental approach...
Chromosomal translocations leading to deregulated expression of ETS transcription factors are frequent in prostate tumors. Here, we report a novel mechanism oncogenic activation the factor ESE1/ELF3 was overexpressed human primary and metastatic It mediated transforming phenotypes vitro vivo induced an inflammatory transcriptome with changes relevant pathways. by interleukin (IL)-1β through NF-κB crucial mediator phenotypic transcriptional IL-1β cancer cells. This linkage interaction...
Mutations and deletions in components of ubiquitin ligase complexes that lead to alterations protein turnover are important mechanisms driving tumorigenesis. Here we describe an alternative mechanism involving upregulation the microRNA miR-424 leads impaired ubiquitination degradation oncogenic transcription factors prostate cancers. We found targets E3 COP1 identified STAT3 as a key substrate promoting tumorigenic cancer stem-like properties epithelial cells. Altered due function led...
Abstract Although cancer stem-like cells (CSC) are thought to be the most tumorigenic, metastatic, and therapy-resistant cell subpopulation within human tumors, current therapies target bulk tumor while tending spare CSC. In seeking understand mechanisms needed acquire maintain a CSC phenotype in prostate cancer, we investigated connections between ETS transcription factor ESE3/EHF, Lin28/let-7 microRNA axis, this malignancy. normal cells, found that ESE3/EHF bound repressed promoters for...
Ets2 is a member of the Ets family transcription factors that in humans comprise 25 distinct members. Various Ets-domain have been implicated cancer development. expressed prostate and breast cells thought to role promoting growth survival these cell types. However, definitive mechanisms whereby acts are still unclear. Structural functional similarities as well overlapping DNA binding specificities complicate identification specific roles various factors. In this study, we used...
Extracellular vesicles (EVs) are relevant means for transferring signals across cells and facilitate propagation of oncogenic stimuli promoting disease evolution metastatic spread in cancer patients. Here, we investigated the release miR-424 circulating small EVs or exosomes from prostate patients assessed functional implications multiple experimental models. We found higher frequency positive with compared to primary tumors BPH. Release was enhanced cell lines (LNCaPabl), transgenic mice...
Abstract Driver genes with a mutually exclusive mutation pattern across tumor genomes are thought to have overlapping roles in tumorigenesis. In contrast, we show here that prostate cancer driver alterations involving the ERG transcription factor and ubiquitin ligase adaptor SPOP synthetic sick. At molecular level, incompatible pathways driven by opposing functions SPOP. upregulates wild type dampen androgen receptor (AR) signaling sustain activity through degradation of bromodomain histone...
Deregulated activity of transcription factors (TFs) the Sp/KLF family, like Sp1, Sp3 and Sp4, consequent over-expression Sp-regulated genes occur frequently in human cancers. This provides rationale for development inhibitors Sp TFs as cancer therapeutics. Mithramycin A (MTM-A) is a natural polyketide that binds GC-rich DNA sequences, inhibits exhibits potent antitumor experimental systems. However, clinical use MTM-A limited by severe toxicity compound. Here, we studied two analogues, which...
Enhancement of cellular senescence in tumours triggers a stable cell growth arrest and activation an antitumour immune response that can be exploited for cancer therapy. Currently, there are only limited number targeted therapies act by increasing cancers, but the majority them not selective also target healthy cells. Here we developed chemogenomic screening to identify compounds enhance PTEN-deficient cells without affecting normal By using this approach, identified casein kinase 2 (CK2) as...
Abstract Cancer stem cells (CSC) contribute to disease progression and treatment failure in prostate cancer because of their intrinsic resistance current therapies. The transcription factors NF-κB STAT3 are frequently activated advanced sustain expansion CSCs. EC-70124 is a novel chimeric indolocarbazole compound generated by metabolic engineering the biosynthetic pathways glycosylated indolocarbazoles, such as staurosporine rebeccamycin. In vitro kinome analyses revealed that acted...
// Domenico Albino 1, 2 , Gianluca Civenni Simona Rossi Abhishek Mitra Carlo V. Catapano 2, 3 Giuseppina M. Carbone 1 Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), Bellinzona, Switzerland Southern (IOSI), Department Oncology, Faculty Medicine, University Lausanne, Correspondence to: Carbone, email: pina.carbone@ior.iosi.ch Keywords: ETS transcription factor, ESE3/EHF, IL-6, cancer stem cells, prostate Received: July 15, 2016 Accepted: October 03,...
Abstract The TMPRSS2-ERG gene fusion is the most frequent alteration observed in human prostate cancer. However, its role disease progression still unclear. In this study, we uncover an important mechanism promoting ERG oncogenic activity. We show that methylated by Enhancer of zest homolog 2 (EZH2) at a specific lysine residue (K362) located within internal auto-inhibitory domain. Mechanistically, K362 methylation modifies intra-domain interactions, favors DNA binding and enhances...